Status:
UNKNOWN
Speech-in-Noise Treatments for Hypophonia in Parkinson's Disease
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions:
Parkinson Disease
Speech Disorders
Eligibility:
All Genders
45-85 years
Phase:
PHASE2
Brief Summary
Hypophonia, or reduced speech intensity, is the most prevalent speech symptom in Parkinson's disease (PD) and often leads to significant difficulty communicating in most social situations. Behavioural...
Detailed Description
Parkinson's disease is one of the most common neurodegenerative diseases and is associated with several disabling motor and non-motor symptoms. About 70% of individuals with PD will develop speech imp...
Eligibility Criteria
Inclusion
- Diagnosed with idiopathic PD and hypophonia by a neurologist at least 6 months prior to participation.
- Stabilized on antiparkinsonian medication.
- Good general health.
- 45-85 years old.
- Pass a 50 dB hearing screening and cognitive screening (\>20/30 on MOCA).
- Proficient enough in English to participate in speech testing.
Exclusion
- History of stroke or an additional neurological or motor control disorder.
- History of speech impairment that is unrelated to PD.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04323085
Start Date
July 1 2020
End Date
December 1 2021
Last Update
March 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
LawsonHRI
London, Ontario, Canada, N6G 1H1